San Diego, California–(Newsfile Corp. – September 22, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug (“IND“) application to the U.S. Food and Drug Administration (“FDA“) to evaluate its clinical candidate…


Previous articlePsychedelics: Past, Present, Future – Webinar
Next articleMeet Microdosing TikTok—And Why the Community Matters